ClinicalTrials.gg
CompletedNCT02091882OSMITTERUpdated Oct 26, 2021Results posted

Substudy of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1)

A Phase 4 interventional study of Placebo and Combination product of Aripiprazole + IEM + Sensor + MIND1 Application in Device Latency, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-10-26.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study was to determine the accuracy of IEM detection by the MIND1 System by completing a series of Patch applications and IEM ingestions in the clinic.

Read the detailed description

The OSMITTER study protocol was designed as a master protocol governing multiple substudies for the rapid assessment of candidate subcomponents for the MIND1 System. This substudy was conducted to determine the accuracy of IEM detection by the MIND1 System by completing a series of Patch applications and IEM ingestions in the clinic.

02

Conditions studied

  • Device Latency

Keywords

  • OPC-14597 Digital
  • Aripiprazole
  • Medical Information Device #1 System (MIND1)
  • Ingestible Event Marker
03

In context

Lead sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.

Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males or healthy non-pregnant females 18 to 65 years of age at the time of who are willing to either practice abstinence or 2 barrier methods of or 1 barrier method and an oral contraceptive method
  • Participants must be in good general health (not suffering from a serious chronic mental or physical disorder that has required or may in the near future require urgent medical care)
  • between 19 to 32 kg/m\^2
  • Ability to eat the high-fat meal

Exclusion criteria

Exclusion Criteria:

  • Participants with a history of skin sensitivity to adhesive medical tape or metals
  • Participants who, in the opinion of the investigator, is acutely psychotic or manic and has symptoms currently requiring hospitalization
  • Participants with a history or evidence of a medical condition that would expose him or her to an undue risk of a significant adverse event (AE) or interfere with assessments of safety during the course of the trial
  • Participants have received any product within the last 30 days.
  • Participants has a current history of drug or alcohol dependence that meets , Fourth Edition, Text Revision (DSM-IV-TR) criteria
  • Participants has the presence of cognitive impairment
  • Participants currently taking antipsychotic medication
  • Participants with a terminal illness
  • Participants with a history of chronic dermatitis
  • Participants with a history of gastrointestinal surgery that could impair absorption
  • Female participants who are breastfeeding and/or who have a positive serum pregnancy test result prior to receiving trial medications
  • Sexually active women of (WOCBP) who will not commit to using 2 forms of approved methods or who will not remain abstinent during this trial and for 30 days following the last dose of trial medication
  • Sexually active males who will not commit to using 2 of the approved birth control methods or who will not remain abstinent for the duration of the trial and for 90 days following the last dose of trial medication
  • No permanent physical residence
  • After resting for ≥3 minutes, have a sitting systolic blood pressure \<100 or ≥150 millimeters of mercury (mmHg) and/or diastolic blood pressure \<50 or ≥90 mmHg
  • After resting for ≥3 minutes, have a sitting pulse rate \<35 or >100 beats per minute
  • Participants who, in the opinion of the investigator, should not participate in the trial
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Aripiprazole IEM Tablet + Placebo IEM Tablet + MIND1 System

    Participants were placed a patch by the clinical staff prior to each ingestible event marker (IEM) tablet ingestion. Participants received one IEM tablet approximately every 2 hours, for a total of 4 ingestions on Day 1 at 0, 2, 4 and 6 hours. Following placement of the patch by clinic staff, participants ingested one 10 mg aripiprazole-embedded IEM tablet without food at Hour 0, one placebo-embedded IEM tablet without food at approximately Hour 2, one placebo-embedded IEM tablet with a high fat meal at approximately Hour 4, and one placebo-embedded IEM tablet without food at approximately Hour 6. Clinic staff recorded the time of each ingestion of an IEM and the time detected by MIND1 System.

    Drug: Placebo · Combination Product: Combination product of Aripiprazole + IEM + Sensor + MIND1 Application

Interventions

  • DrugPlacebo

    Oral placebo-embedded IEM tablet.

  • Combination productCombination product of Aripiprazole + IEM + Sensor + MIND1 Application

    Drug page: Aripiprazole

    Combination product of aripiprazole tablet embedded with sensor and wearable patch with MIND1 system on smartphone

    Also known as: Abilify MyCite®

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Accuracy of Ingestible Event Marker (IEM) Detection

    The accuracy of IEM signal detection was collected by comparing the time of ingestion recorded by MIND1 system at different timepoints with the time recorded by the clinic staff. The percentage of participants with the accurate time of IEM detection are reported for each ingestion separately at Hours 0, 2, 4 and 6 on Day 1.

    Time frame: Up to Hour 6 on Day 1

Secondary outcomes

  1. Latency Period From Ingestion to Detection of IEM

    Latency period was defined as the time in minutes from the IEM ingestion for both aripiprazole and placebo to the time of detection of IEM by MIND1 system on a smartphone. The latency period is calculated as the difference in the time recorded by the clinic staff of IEM ingestion and the time displayed on the MIND1 application.

    Time frame: Day 1 at Hours 0, 2, 4, 6

07

Results

Posted Oct 26, 2021

Participant flow

This trial was conducted on 30 healthy participants at one trial site in the United States from 21 March 2014 to 18 April 2014.

Participant flow — Overall Study
MilestoneAripiprazole IEM Tablet + Placebo IEM Tablet + MIND1 System
Started30
Completed30
Not completed0

Outcome measures

PrimaryPercentage of Participants With Accuracy of Ingestible Event Marker (IEM) Detection

The accuracy of IEM signal detection was collected by comparing the time of ingestion recorded by MIND1 system at different timepoints with the time recorded by the clinic staff. The percentage of participants with the accurate time of IEM detection are reported for each ingestion separately at Hours 0, 2, 4 and 6 on Day 1.

Time frame:
Up to Hour 6 on Day 1
Reported as:
Number · percentage of participants
Percentage of Participants With Accuracy of Ingestible Event Marker (IEM) Detection
percentage of participantsAripiprazole IEM Tablet + Placebo IEM Tablet + MIND1 System
Day 1, Hour 073.3 (57.0 to 86.0)
Day 1, Hour 263.3 (46.7 to 77.9)
Day 1, Hour 476.7 (60.6 to 88.5)
Day 1, Hour 693.3 (80.5 to 98.8)
SecondaryLatency Period From Ingestion to Detection of IEM

Latency period was defined as the time in minutes from the IEM ingestion for both aripiprazole and placebo to the time of detection of IEM by MIND1 system on a smartphone. The latency period is calculated as the difference in the time recorded by the clinic staff of IEM ingestion and the time displayed on the MIND1 application.

Time frame:
Day 1 at Hours 0, 2, 4, 6
Reported as:
Median · minutes
Latency Period From Ingestion to Detection of IEM
minutesAripiprazole IEM Tablet + Placebo IEM Tablet + MIND1 System
Day 1, Hour 04 (1 to 14)
Day 1, Hour 21 (0 to 3)
Day 1, Hour 41 (0 to 2)
Day 1, Hour 61 (0 to 4)

Adverse events

Collected over From Day 1 to 2-week safety follow up (Day 15). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aripiprazole IEM Tablet + Placebo IEM Tablet + MIND1 System0/30 (0%)0/30 (0%)5/30 (16.7%)
Most frequent other events
Most frequent other events
EventAripiprazole IEM Tablet + Placebo IEM Tablet + MIND1 System
NauseaGastrointestinal disorders5/30

Baseline characteristics

Safety Sample included all participants who ingested at least one aripiprazole + IEM tablet or placebo + IEM tablet.

Age, Continuous
Age, Continuous(Years)Aripiprazole IEM Tablet + Placebo IEM Tablet + MIND1 System
Mean39.8 ± 15.3
Sex: Female, Male
Sex: Female, Male(Participants)Aripiprazole IEM Tablet + Placebo IEM Tablet + MIND1 System
Female17
Male13
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Aripiprazole IEM Tablet + Placebo IEM Tablet + MIND1 System
Hispanic or Latino4
Not Hispanic or Latino26
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Aripiprazole IEM Tablet + Placebo IEM Tablet + MIND1 System
American Indian or Alaska Native0
Asian4
Native Hawaiian or Other Pacific Islander1
Black or African American3
White16
More than one race0
Unknown or Not Reported6
08

Study locations

1 site
  • Walnut Creek, California 94598, United States
09

References and documents

Publications

  • Rohatagi S, Profit D, Hatch A, Zhao C, Docherty JP, Peters-Strickland TS. Optimization of a Digital Medicine System in Psychiatry. J Clin Psychiatry. 2016 Sep;77(9):e1101-e1107. doi: 10.4088/JCP.16m10693. PubMed 27487251 ↗
  • Profit D, Rohatagi S, Zhao C, Hatch A, Docherty JP, Peters-Strickland TS. Developing a Digital Medicine System in Psychiatry: Ingestion Detection Rate and Latency Period. J Clin Psychiatry. 2016 Sep;77(9):e1095-e1100. doi: 10.4088/JCP.16m10643. PubMed 27379966 ↗

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/

Data sharing details ↗ · clinical-trials.otsuka.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2014 to primary completion in Apr 2014, 0 months.

Results were first posted in Oct 2021, 7 years 6 months after primary completion. A results delay was requested in Mar 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2014
First posted
Mar 19, 2014
StartActual
Mar 21, 2014
Primary completionActual
Apr 18, 2014
CompletionActual
Apr 18, 2014
Results delay requested
Mar 25, 2015
Results first posted
Oct 26, 2021
Last update
Oct 26, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02091882
Responsible party
Sponsor
First posted
Mar 19, 2014
Start date
Mar 21, 2014
Primary completion
Apr 18, 2014
Completion
Apr 18, 2014
Results posted
Oct 26, 2021
Last update
Oct 26, 2021

Study contacts

Study Director
study director · Otsuka Pharmaceutical Development & Commercialization

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aripiprazole

Start the discussion